De Latour RP et al.Clinical breakthrough hemolysis (BTH) during monotherapy with the oral factor B inhibitor iptacopan is generally not severe and managed without treatment discontinuation: 48-week data from the phase III Apply-PNH and Appoint-PNH trials in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2023;142(suppl 1):1338. Abstract
Hillmen P et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2021;384(11):1028-37. Abstract
Kulasekararaj AG, Lazana I. Paroxysmal nocturnal hemoglobinuria: Where are we going. Am J Hematol 2023;98(S4):33-43. Abstract
Kulasekararaj AG et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study. Blood 2019;133(6):540-9. Abstract
Lee JW et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): A double-blind, randomised, phase 3 trial. Lancet Haematol 2023;10(12):e955-65. Abstract
Lee JW et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood 2019;133(6):530-9. Abstract
Liu H et al. Results from the first phase 3 crovalimab (C5 inhibitor) study (COMMODORE 3): Efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 2022;140(1):714-6. Abstract
Risitano AM et al. Oral complement factor B inhibitor iptacopan monotherapy improves hemoglobin to normal/near-normal levels in paroxysmal nocturnal hemoglobinuria patients naïve to complement inhibitors: Phase III APPOINT-PNH trial. EBMT 2023;Abstract O135.
Röth A et al. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Am J Hematol 2024;99(9):1768-77. Abstract
Scheinberg P et al. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2024;99(9):1757-67. Abstract